We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024
25 Apr 2024 - 27 Apr 2024

Insulin Sensitivity and Adiponectin Level Predict Insulin Therapy Response

By LabMedica International staff writers
Posted on 03 Oct 2019
Print article
Image: Consistent HbA1c improvement was associated with higher insulin sensitivity in the TODAY study (Photo courtesy of Diabnext).
Image: Consistent HbA1c improvement was associated with higher insulin sensitivity in the TODAY study (Photo courtesy of Diabnext).
A cohort of youths with obesity and type 2 diabetes who initiated insulin therapy experienced highly variable HbA1c outcomes, with greater insulin sensitivity and higher adiponectin levels associated with improved glycemic response.

Previous evaluation of risk factors for glycemic failure in the Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) study indicated that higher failure rates were associated with beta-cell dysfunction, higher HbA1c at randomization and African American race. The change in total and high molecular weight adiponectin concentrations over the first six months post-randomization in TODAY was predictive of the responsiveness to oral diabetes therapy.

Scientists at the Baylor College of Medicine (Houston, TX, USA) and their associates analyzed data from 253 youths aged 10 to 17 years with obesity and type 2 diabetes for at least two years participating in TODAY study who were enrolled between July 2004 and February 2009, who had a mean of 3.9 visits since initiation of insulin therapy (64% girls; mean age at randomization, 14 years; mean HbA1c at insulin initiation, 10.1%).

Insulin glargine was titrated up to 1 U/kg per day (maximum, 100 U) until fasting glucose levels measured by self-monitoring reached 70 mg/dL to 150 mg/dL. Add-on insulin glargine therapy was considered unsuccessful if titration of therapy did not bring fasting blood glucose to target within one month or if HbA1c was greater than 8% at three months or 7% at six months.

The team reported that within 1‐year post-insulin initiation, 33.2% of participants had a consistent HbA1c decrease of ≥0.5%, 46.2% changed HbA1c <0.5%, and 20.6% had an increase ≥0.5%. At randomization into TODAY and at time of insulin initiation, the three glycemia groups were similar in age, sex, race‐ethnicity, pubertal stage, BMI z‐score, diabetes duration, and insulin secretion indices. Consistent HbA1c improvement was associated with higher insulin sensitivity (1/fasting insulin) at randomization and at time of failure, higher adiponectin at randomization, and was not associated with indices of β‐cell function.

The authors concluded that response to add‐on insulin was highly variable among youth in the TODAY study. Greater insulin sensitivity and higher adiponectin concentrations at randomization were associated with improved glycemic control after initiation of insulin. Fida Bacha, MD, an associate professor of pediatrics and nutrition and first author of the study, said, “Youth with type 2 diabetes who required insulin therapy continued to have worse diabetes control over time compared with those who maintained glycemic control on metformin alone.” The study was originally published online on August 16, 2019, in the journal Pediatric Diabetes.

Related Links:
Baylor College of Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Molecular Diagnostics

view channel
Image: AI analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer (Photo courtesy of Adobe Stock)

Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer

Ovarian cancer is one of the most common causes of cancer deaths among women and has a five-year survival rate of around 50%. The disease is particularly lethal because it often doesn't cause symptoms... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Pathology

view channel
Image: ‘Virtual biopsy’ allows clinicians to analyze skin noninvasively (Photo courtesy of Stanford Medicine)

Virtual Skin Biopsy Determines Presence of Cancerous Cells

When dermatologists spot an unusual mark on a patient's skin, they face a choice: monitor it for some time or remove it for biopsy. Similarly, when removing breast tumors, surgeons must send excised tissues... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.